CLINICAL TRIAL SUMMARY

MDACC Study No:2012-0413 (clinicaltrials.gov NCT No: NCT01793051)
Title:A Phase II Randomized Study of the Efficacy of Minocycline vs. Placebo to Reduce Symptom Burden during Maintenance Therapy for Multiple Myeloma
Principal Investigator:Robert Orlowski
Treatment Agent:Minocycline
Study Status:Open
Study Description:The goal of this clinical research study is to learn if minocycline can help
reduce the symptoms reported by patients with MM who receive therapy with
lenalidomide.

Minocycline is an antibiotic and has been shown to interrupt pro-inflammatory
cytokine production, which may help to reduce multiple symptoms.

Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase II
Treatment Agents:Minocycline
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:National Cancer Institute
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Robert Orlowski
Dept:Symptom Research
For Clinical Trial Enrollment:713-745-3470
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults